 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Samsung BioLogics announced on the 4th that it has signed two CMO contracts with Pfizer of the United States.
These are two cases: a new contract worth $704.39 million (about 922.7 billion won) and an additional contract worth $193 million (254.3 billion won) on March 2. Samsung BioLogics has secured about 1.2 trillion won in contract volume, the largest daily amount ever.
As a result, Samsung BioLogics signed a total of 1.08 billion dollars (1.418 trillion won) of CMO contract with Pfizer this year alone.
Samsung BioLogics announced its CMO contract with Pfizer in June that it will produce a long-term portfolio of biosimilar products, including tumors, inflammation and immune treatments, by 2029 at its fourth plant, which began full operation on June 1. The term of the contract is until December 31, 2029.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
